Home› Library› Research summary› Tirzepatide
SURMOUNT-1: what the tirzepatide obesity data showed
A summary of the Phase 3 SURMOUNT-1 obesity trial (NEJM 2022) — design, primary outcomes, dose-response observations, and what the data implies for tirzepatide research.
SURMOUNT-1 is the Phase 3 randomized trial published in the New England Journal of Medicine in 2022 that established tirzepatide as a leading research compound for incretin-based body-weight modulation. The trial enrolled 2,539 adults with obesity (mean BMI 38) and randomized them across four arms: tirzepatide 5 mg, 10 mg, 15 mg, or placebo, administered subcutaneously once weekly for 72 weeks.
What the trial measured
Two co-primary outcomes:
- Percentage change in body weight from baseline to 72 weeks
- Proportion of participants achieving ≥5% body weight reduction at 72 weeks
Secondary measures included waist circumference, blood pressure, lipid panel, glucose, and a basket of metabolic markers.
Headline findings
| Arm | Mean weight change at 72 weeks | ≥5% reduction | ≥20% reduction |
|---|---|---|---|
| Placebo | −3.1% | 35% | 3% |
| Tirzepatide 5 mg | −15.0% | 85% | 27% |
| Tirzepatide 10 mg | −19.5% | 89% | 40% |
| Tirzepatide 15 mg | −20.9% | 91% | 50% |
The dose-response curve is approximately linear through 10 mg, then begins to flatten between 10 and 15 mg — useful information for research designs deciding between mid- and high-dose arms.
Titration protocol
SURMOUNT-1 used a slow titration schedule: 2.5 mg weekly for 4 weeks, then +2.5 mg every 4 weeks until the target maintenance dose was reached. This 20-week titration was designed to manage gastrointestinal adverse events, which are the dominant tolerability signal for incretin agonists. Most published research protocols using tirzepatide follow this titration pattern; bypassing it accelerates GI side effects significantly.
Adverse events
The most common events across all arms were gastrointestinal — nausea (24–33% in tirzepatide arms vs. 9% placebo), diarrhea (19–23% vs. 7%), and constipation (11–17% vs. 6%). Most events were mild-to-moderate and occurred during titration. Discontinuation rates due to adverse events were 4–7% across tirzepatide arms versus 2.6% in placebo.
What it implies for research
A few methodological takeaways:
- Dose matters more than commonly assumed. The gap between 5 mg and 15 mg in percentage reduction was ~6 percentage points — material when comparing arms.
- 72-week endpoints differ from 16- or 24-week endpoints. Effect size grows steadily through the first 60+ weeks. Short-duration research understates the achievable signal.
- Titration is non-negotiable. Research models that don't titrate produce muddier tolerability data and higher attrition.
- Placebo arms still lose weight. The placebo arm lost 3% — driven by trial-protocol behavioral changes (diet/activity counseling). Don't compare absolute tirzepatide numbers to a no-intervention baseline.
Limitations of the trial
SURMOUNT-1 was conducted in adults without diabetes and excluded participants with HbA1c > 6.5%. The follow-up duration (72 weeks) is long for a Phase 3 weight trial but short for an obesity intervention — durability beyond 2 years was not characterized. Generalizability to populations with diabetes is captured in the parallel SURPASS series.
Notes
This is a research summary of published clinical data. It is not a recommendation for any specific research protocol or design. For research use only. Not for human consumption.
Reference
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205–216. PMID: 35658024
Was this helpful?
We reply to every research inquiry.